Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus
© 2021 American College of Rheumatology..
OBJECTIVE: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS-CoV-2 vaccine (Sinovac-CoronaVac) and the influence of different medications in SLE. Safety was also assessed.
METHODS: We conducted a prospective controlled study of 232 SARS-CoV-2-naive SLE patients and 58 SARS-CoV-2-naive controls who were vaccinated with 2 doses of Sinovac-CoronaVac with a 28-day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed.
RESULTS: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108-0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107-0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events.
CONCLUSION: Sinovac-CoronaVac has a moderate immunogenicity in SARS-CoV-2-naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine-booster dose (ClinicalTrials.gov identifier: NCT04754698).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Arthritis care & research - 74(2022), 4 vom: 16. Apr., Seite 562-571 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuki, Emily F N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 16.07.2022 published: Print-Electronic ClinicalTrials.gov: NCT04754698 Citation Status MEDLINE |
|---|
| doi: |
10.1002/acr.24824 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333436792 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333436792 | ||
| 003 | DE-627 | ||
| 005 | 20231225221644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acr.24824 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333436792 | ||
| 035 | |a (NLM)34806342 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuki, Emily F N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04754698 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS-CoV-2 vaccine (Sinovac-CoronaVac) and the influence of different medications in SLE. Safety was also assessed | ||
| 520 | |a METHODS: We conducted a prospective controlled study of 232 SARS-CoV-2-naive SLE patients and 58 SARS-CoV-2-naive controls who were vaccinated with 2 doses of Sinovac-CoronaVac with a 28-day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed | ||
| 520 | |a RESULTS: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108-0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107-0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events | ||
| 520 | |a CONCLUSION: Sinovac-CoronaVac has a moderate immunogenicity in SARS-CoV-2-naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine-booster dose (ClinicalTrials.gov identifier: NCT04754698) | ||
| 650 | 4 | |a Controlled Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Borba, Eduardo F |e verfasserin |4 aut | |
| 700 | 1 | |a Pasoto, Sandra G |e verfasserin |4 aut | |
| 700 | 1 | |a Seguro, Luciana P |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Carla G S |e verfasserin |4 aut | |
| 700 | 1 | |a Medeiros-Ribeiro, Ana Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Clovis A |e verfasserin |4 aut | |
| 700 | 1 | |a de Andrade, Danieli C O |e verfasserin |4 aut | |
| 700 | 1 | |a Kupa, Leonard de Vinci K |e verfasserin |4 aut | |
| 700 | 1 | |a Betancourt, Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoglio, Isabela |e verfasserin |4 aut | |
| 700 | 1 | |a Valim, Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Hoff, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Formiga, Francisco F C |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrosa, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Kallas, Esper G |e verfasserin |4 aut | |
| 700 | 1 | |a Aikawa, Nadia E |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfa, Eloisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis care & research |d 2010 |g 74(2022), 4 vom: 16. Apr., Seite 562-571 |w (DE-627)NLM195433068 |x 2151-4658 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:4 |g day:16 |g month:04 |g pages:562-571 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acr.24824 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 4 |b 16 |c 04 |h 562-571 | ||